靶向AKT/m-TOR通路：癌症治疗耐药的生物标志物——AKT/m-TOR通路与癌症治疗耐药
Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy-- AKT/m-TOR Pathway and Resistance to Cancer Therapy.
作者信息
Spirina Liudmila V, Kondakova Irina V, Tarasenko Natalia V, Slonimskaya Elena M, Usynin Evgeny A, Gorbunov Alexey K, Yurmazov Zahar A, Chigevskaya Svetlana Yu
机构信息
Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia.
Department of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russia.
出版信息
Zhongguo Fei Ai Za Zhi. 2018 Jan 20;21(1):63-66. doi: 10.3779/j.issn.1009-3419.2018.01.09.
Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.
对癌症治疗的耐药性仍然是成功治疗癌症的主要限制因素。关于乳腺癌和前列腺癌治疗耐药性已有许多发表的研究；然而，目前尚无与耐药性相关的分子标志物数据。关于将AKT/m-TOR信号通路成分作为预测耐药性的标志物，已有相互矛盾的数据报道。AKT/m-TOR信号通路参与多种人类癌症的发生发展；其激活与细胞增殖、血管生成、细胞凋亡以及治疗耐药性有关。AKT/m-TOR信号通路中的分子改变为识别与癌症治疗耐药性发展相关的通用标志物提供了一个平台。
Zotero 插件